Think only the wealthy can afford personalized cancer treatment? Think again.

In this powerful episode, Dr. Dino Prato, founder of Envita Medical Centers, exposes the true cost of cancer care — not just in dollars, but in missed outcomes. From FDA fast-tracked drugs with minimal survival benefit to hospital and PBM markups that can reach 600%, he breaks down the economics of the cancer industry and compares them with precision-based care at Envita.

🎯 What You’ll Learn:

• Why most approved cancer drugs add just 3–5 months of life on average
• How pharmacy benefit managers (PBMs) and hospitals inflate drug costs by hundreds of percent
• Real-world examples of patients who paid 70–80% less and saw tumor clearance after 12 weeks
• What “N-of-1” precision medicine means: RNA, DNA, immune profiling, and spatial biology — built just for you
• How employers and health-sharing models are using Envita’s model to lower costs and improve care access

📊 In our clinical experience, this model showed 35x better outcomes, 43x better quality of life, and 95x fewer side effects — all at significantly lower cost.*
(*See Outcomes Disclaimer below)

"You can’t afford the wrong treatment. But the right one may cost less than you think.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493